Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study

References

• Grove CS, Vassiliou GS. Acute myeloid leukemia: a paradigm for the clonal evolution of cancer? Dis Model Mech. 2014;7(8):941–951.
   PubMed Web of Science ®Google Scholar
• Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard dose idarubicin with high dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML 201 study. Blood. 2011;117:2358–2365. doi:10.1182/blood-2010-03-273243
   PubMed Web of Science ®Google Scholar
• Wang ES. Common fungal infection in patients with leukemia. Clin Adv Hematol Oncol. 2017;5(15):352.
   Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guidline for the management of candidiasis: 2016 update by the Infectious Disease Society of America. Clin Infect Dis. 2016;62(4):e1–e50.
   PubMed Web of Science ®Google Scholar
• Shao PL, Huang LM, Hsueh PR. Recent advances and challenges in the treatment of invasive fungal infection. Int J Antimicrob Agents. 2007;30(6):487–489. doi:10.1016/j.ijantimicag.2007.07.019
   PubMed Web of Science ®Google Scholar
• Paul S, Kannan I, Mohanram K. Eextensive ERG11 mutation associated with fluconazole- resistant Candida albicans isolated from HIV infected patients. Curr Med Mycol. 2019;5(3):1.
   Google Scholar
• Goncalves SS, Souza ACR, Chowdhary A, Meis JF, Colombo AL. Epidemiology and molecular mechanism of antifungal resistant in Candida and Aspergillus. Mycoses. 2016;59(4):198–219.
   Web of Science ®Google Scholar
• Kanafani ZA, Perfect JR. Resistance to antifungal agents: mechanism and clinical impact. Clin Infect Dis. 2008;46(1):120–128. doi:10.1086/524071
   PubMed Web of Science ®Google Scholar
• Rogers PD, Barker KS. Genome wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrob Agents Chemother. 2003;47(4):1220–1227. doi:10.1128/AAC.47.4.1220-1227.2003
   PubMed Web of Science ®Google Scholar
• Akins RA. An update on antifungal target and mechanism of resistance in Candida albicans. Med Mycol. 2005;43(4):285–318. doi:10.1080/13693780500138971
   Web of Science ®Google Scholar
• Liu S, Yue L, Gu W, Li X, Zhang L, Sun S. Synergesic effect pffluconazole and calcium channel blocker against resistant Candida albicans. PLoS One. 2016;11(3):e0150859. doi:10.1371/journal.pone.0150859
   PubMed Web of Science ®Google Scholar
• Chen X, Ren B, Chen M, et al. ASDCD:Antifugal synergistic drug combination database. PLoS One. 2014;9(1):e86499. doi:10.1371/journal.pone.0086499
   PubMed Web of Science ®Google Scholar
• Rodrgues- Diez R, Gonzales-Guerrero C, Ocana-Salceda C, et al. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. Sci Rep. 2016;6(1):1–16. doi:10.1038/s41598-016-0001-8
   Web of Science ®Google Scholar
• Pina-vaz C, Sansonetty F, Roderigues AG, Martinez-de-oliveria J, Fonseca AF, Mardh P-A. Antifungal activity of ibuprofen alone, and in combination with fluconazole against candida species. J Med Microbiol. 2000;49(9):831–840. doi:10.1099/0022-1317-49-9-831
   Web of Science ®Google Scholar
• Hersh E, Hammond B, Fleury A. Antimicrobial activity of flurbirofen, and ibuprofen in vitro against six common periodontal pathogens. J Clin Dent. 1991;3(1):1–5.
   Google Scholar
• Ahangarkani F, Khodavaisy S, Mahmoudi S, et al. Indifferent effect of non-steroidal anti-inflammatory drugs (NSAIDs) combined with fluconazole against multidrug resistant Candida auris. Curr Med Mycol. 2019;5(3):26.
   Google Scholar
• Retsky M, Rogers R, Demicheli R, et al. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer replace: particular relevance to triple negative subgroup. Breast Cancer Res Treat. 2012;134(2):881–888. doi:10.1007/s10549-012-2094-5
   Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2008:130–139.
   Google Scholar
• Rotstein S, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian fluconazole prophylaxis study group. Clin Infect Dis. 1999;28:331–340. doi:10.1086/515128
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Dianosis and management of acute myeloid leukemia in adults: recommendation from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Power D, Johnsen J. Difco TM, BBL TM, Manual: Manual of Microbiological Culture Media. Sparks: Becton Dickinson and company; 2009.
   Google Scholar
• Marinho SA, Teixeira AB, Santos OS, et al. Identification of Candida spp. by phenotypic tests and PCR. Braz j Microbiol. 2010;41(2):286=294. doi:10.1590/S1517-83822010000200004
   Web of Science ®Google Scholar
• Pincus D, Orenga S, Chatellier S. Yeast identification past present and future methods. Med Mycol. 2007;45(2):97–121. doi:10.1080/13693780601059936
   PubMed Web of Science ®Google Scholar
• Mannarelli BM, Kurtzman CP. Rapid identification of Candida albicans and other human pathogenic yeast by using short oligonucleotides in a PCR. J Clin Microbiol. 1998;1(36):1634–1641. doi:10.1128/JCM.36.6.1634-1641.1998
   Web of Science ®Google Scholar
• CLSI. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeast; Approved Guideline. M44=A2 ed. Wayne, PA: Clinical and laboratory standards Institute; 2009.
   Google Scholar
• Ellis D. Antifungal susceptibility profile Australian antifungal susceptibility data for Candida isolates from recurrent vulvovaginal candidiasis (2007–2009) using the CLIS M44-A2 disc susceptibility standard for yeast. Mycology online. Adelaide, Australia: The University of Adelaide; 2011.
   Google Scholar
• Meletiadis J, Mouton J, Lagrou JW, Hamal K, Petr Guinea J; EUCAST. Subcommittee on Antifungal susceptibility testing of the ESCMID European committee for Antimicrobial susceptibility testing. Def. 2017;7(1).
   Google Scholar
• Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1. doi:10.1093/jac/dkg301
   PubMed Web of Science ®Google Scholar
• Ghen Y-L, Lehman VN, Averette AF, Perfect JR, Heitman J. Posaconazole exhibits In vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. PLoS One. 2013;3:e57672.
   Google Scholar
• Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, Mcnicholas PM. Application of real time quantitative PCR to molecular analysis of Candida albicans strain exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother. 2004;48:2124–2131. doi:10.1128/AAC.48.6.2124-2131.2004
   PubMed Web of Science ®Google Scholar
• Rocha MFG, Banderia SP, De Alencar LP, et al. Azole resistance in Candida albicans from animals: highlights on efflux pump activity and gene over-expression. Mycoses. 2017;60:462–468. doi:10.1111/myc.12611
   PubMed Web of Science ®Google Scholar
• Pfaffi MW. A new mathematical model for relative quantification in real time PCR. Nucleic Acids Res. 2001;29(9):e45–e. doi:10.1093/nar/29.9.e45
   Web of Science ®Google Scholar
• Ibrahim AS, Khaled HM, Mikhail NM, Baraka H, Kamel H. Cancer Incidence in Egypt: resultsof the National Population –Based Cancer Registry Program. J Cancer Epidemiol. 2014;2014:1–8. doi:10.1155/2014/437971
   Google Scholar
• Acharya UH, Kanaan MN, Cui H, Roe DJ. Does the region of diagnosis correlate with overall survival in patients with Acute Myeloid Leukemia (AML)-a SEER review of AML diagnosis from 2004–2007. Blood. 2014;124:1291. doi:10.1182/blood.V124.21.1291.1291
   Google Scholar
• Zawam H, Salama R, Alsirafy SA, Bishr MK. Treatment outcome of Acute Myeloid Leukemia in Egypt: adeveloping country perspective. Int J Cancer Treat. 2018;1(1):53–59.
   Google Scholar
• Sekeres MA, Elson P, Kalaycio ME. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113:28–36. doi:10.1182/blood-2008-05-157065
   PubMed Web of Science ®Google Scholar
• Donadu MG, Usai D, Marchetti M, et al. Antifungal activity of oil macerates of North Sardinia plants against Candida species isolated from clinical patients with candidiasis. Nat Prod Res. 2020;34(22):3280–3284. doi:10.1080/14786419.2018.1557175
   PubMed Web of Science ®Google Scholar
• Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002;2(2):73–85. doi:10.1016/S1473-3099(02)00181-0
   PubMed Web of Science ®Google Scholar
• Farhan MA, Moharram AM, Salah T, Shaaban OM. Relation between antifungal resistance and enzymatic activity of yeast causing oral and vaginal mycosis. Assiut Univ J Bot Microbiol. 2019;48(1):1–16.
   Google Scholar
• Farhan MA, Moharram AM, Salah T, Shaaban OM. Types of yeasts that cause vulvovaginal candidiasis in chronic users of corticosteroids. Med Mycol. 2019;57(6):681–687. doi:10.1093/mmy/myy117
   PubMed Web of Science ®Google Scholar
• Pfaller M, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome of Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interactive MIC breakpoint. J Clin Microbiol. 2008;46(8):2620–2629. doi:10.1128/JCM.00566-08
   PubMed Web of Science ®Google Scholar
• Ehrstrom S, Yu A, Rylander E. Glucose in vaginal secretion before and after oral glucose tolerance testing in women with and without recurrent vulvovaginal candidiasis. Obstet Gynecol. 2006;108(6):1432–1437. doi:10.1097/01.AOG.0000246800.38892.fc
   PubMed Web of Science ®Google Scholar
• Lu M, Yan H, Yu C, Yuan L, Sun S. Proton pump inhibitors act synergistically with fluconazole against resistant Candida albicans. Sci Rep. 2020;10(1):498. doi:10.1038/s41598-019-57174-4
   PubMed Web of Science ®Google Scholar
• Sharma M, Biswas D, Kotwal A, et al. Ibuprafen- mediated reversal of fluconazole resistance in clinical isolates of Candida. J Clin Diagn Res. 2015;9(1):DC20.
   Google Scholar
• Usai D, Donadu M, Bua A, et al. Enhancement of antimicrobial activity of pump inhibitor associating drugs. J Infect Dev Ctries. 2019;13(02):162–164. doi:10.3855/jidc.11102
   Web of Science ®Google Scholar
• Tsao S, Rahkhoodaee F, Raymond M. Relative contribution of the candida albicans ABC tr ansporters Cdr1p and Cdr2p to clinical azole rsistence. Antimicrob Agents Chemother. 2009;53(4):1344–1352. doi:10.1128/AAC.00926-08
   PubMed Web of Science ®Google Scholar
• Holmes AR, Lin Y-H, Niimi K, et al. ABC transporters Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole–resistant Candida albicans clinical isolates. Antimicrob Agents Chemother. 2008;52(11):3851–3862. doi:10.1128/AAC.00463-08
   PubMed Web of Science ®Google Scholar
• Niimi K, Maki K, Ikeda F, et al. Overexpression of Candida albicans CDR1, CDR2, orMDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob Agents Chemother. 2006;50(4):1148–1155. doi:10.1128/AAC.50.4.1148-1155.2006
   Web of Science ®Google Scholar
• Xiang M-J, Liu J-Y, Ni P-H, et al. Erg11 mutations associated with azoles resistence in clinical isolates of candida albicans. FEMS Yeast Res. 2013;13(4):386–393. doi:10.1111/1567-1364.12042
   PubMed Web of Science ®Google Scholar